Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-07-21
The filing discloses completion of precision testing for the Company's Intelligent Fingerprinting Drug Screening System as part of its FDA 510(k) submission package. This is a material operational and regulatory milestone—the precision testing of over 1,600 tests across three production runs and three independent sites strengthens the pathway to FDA clearance and planned U.S. market entry in a multi-billion-dollar drug screening market. While the event is clearly operational/regulatory in nature and material to investors, it does not fit neatly into a specific named category (not a restatement, impairment, litigation, or other defined event type), making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Governance Other
confidence 80%
filed 2026-07-21
EX-99.1
707 Cayman Holdings Ltd. is soliciting shareholder approval at an Extraordinary General Meeting scheduled for August 5, 2026, to increase authorized share capital from US$500,000 to US$12,000,000 (a 24-fold increase) by creating approximately 43.3 million additional Class A shares and 4.6 million additional Class B shares. This material capital structure amendment could facilitate future dilutive issuances and significantly affects shareholder interests.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-21
EX-99.1
This press release announces Core AI's strategic advancement of HomeGPT as an AI-powered residential decision platform, expanding its vertical AI application strategy with new capabilities in home design, renovation visualization, and residential purchasing support. The disclosure describes a material operational and strategic initiative—the repositioning and expansion of a key product platform—that would affect a reasonable investor's assessment of the company's business strategy and growth opportunities, though it does not fit the specific categories of M&A activity, earnings results, or executive changes.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-21
FatPipe announced the award of a $7 million contract to provide network edge products and network monitoring services to schools, disclosed under Item 8.01 (Other Events). This is a material operational/commercial milestone representing significant new business in the education and public-sector markets, but does not fit the specific categories of earnings release, M&A activity, or other named event types. The contract award demonstrates business development success and market expansion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-21
The filing discloses the completion of a material acquisition on July 15, 2026, whereby Starco Brands acquired all outstanding capital stock of Custom Foods, LLC (Custom Bakehouse) for $8.0 million in cash plus up to $2.5 million in earn-out consideration. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets," and the press release confirms the transaction is expected to add approximately $20 million in annual revenue, representing a strategically significant vertical integration milestone for the company.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-21
The filing discloses multiple debt transactions under Item 1.01: (1) a $124,200 promissory note from 1800 Diagonal Lending with net proceeds of $100,000 and repayment terms through September 2027; (2) exchange agreements with Streeterville Capital partitioning and converting $330,000 of existing debt into common stock; and (3) a $6,235,000 secured convertible promissory note from Streeterville Capital with complex default and trigger provisions. The primary event is the creation of new direct financial obligations, particularly the substantial Streeterville Capital note, making debt_issuance the most salient classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-21
EX-99.1
DirectBooking Technology has entered into a strategic joint venture agreement with Beijing DeepYou Digital Technology Co., Ltd., with DirectBooking holding 51% equity interest and DeepYou holding 49%. This constitutes a material acquisition or change-of-control transaction under Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition). The announcement explicitly states the parties "will jointly establish a new technology company," representing a significant capital commitment and strategic restructuring that would materially affect investor assessment of the company's direction and financial position.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-21
The filing discloses entry into a material definitive agreement under Item 1.01 whereby the Company issued an unsecured promissory note to its sponsor for up to $250,000 to fund initial business combination costs. Item 2.03 explicitly incorporates this as creation of a direct financial obligation. This is a debt issuance—a new direct financial obligation created by the registrant.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-21
The 6-K discloses the results of an extraordinary general meeting held on July 21, 2026, where shareholders voted on a 1-for-10 share consolidation resolution. The resolution passed with 99.34% of votes cast in favor. Share consolidations are material capital structure changes that affect all shareholders' holdings and voting power, and the filing explicitly reports the voting results by share class and vote count, matching the `shareholder_vote_results` taxonomy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
The Board appointed Maen Razouqi as an additional independent director, effective August 1, 2026. This is a clear executive/director appointment disclosed under Item 5.02(d). While the disclosure also mentions standard director compensation arrangements, the principal action is the appointment of a new board member, making this an exec_appointment event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-21
The filing discloses a Nasdaq listing rule compliance matter under Item 3.01. The Company initially failed to satisfy Nasdaq Listing Rule 5605(c)(2) audit committee composition requirements by the July 2, 2026 deadline, but remedied the deficiency on July 13, 2026 by appointing Daniel Alef as an independent audit committee member. While the appointment itself could be classified as exec_appointment, the salient event is the governance compliance issue and its resolution, making governance_other the most appropriate classification. The matter is material as it relates to continued listing compliance and corporate governance structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-21
Jupiter Neurosciences entered into a definitive Strategic Asset License Agreement with PharmAla Biotech on July 20, 2026, granting an exclusive royalty-bearing license to develop, manufacture, and commercialize ALA-002 products in the United States. The transaction involves $3.3M upfront consideration (cash and equity), up to $23.3M in development milestones, up to $73.3M in commercialization milestones, and 3% royalties on net sales. This constitutes a material acquisition of intellectual property rights and represents a significant strategic transaction for a clinical-stage pharmaceutical company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
The filing discloses results of My Size, Inc.'s 2026 annual stockholder meeting held on July 21, 2026, under Item 5.07. The company reports voting outcomes for five proposals: election of two Class II directors (both passed), an advisory say-on-pay vote (passed), authorization for reverse stock splits up to 1-for-30 (passed), approval of blank check preferred stock authorization (failed to achieve majority of outstanding shares), and ratification of Somekh Chaikin as independent auditor (passed). The failure of the blank check preferred stock proposal is material to investors assessing the company's capital structure flexibility.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-21
Dr. Gregory M. Sullivan, Chief Medical Officer, informed the Company on July 20, 2026 that he will retire from his role effective August 20, 2026. This is a clear executive departure disclosed under Item 5.02, representing the departure of a named officer from the Company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-21
The filing discloses a shareholder letter and press release (Items 7.01 and 9.01) in which management provides strategic commentary on the company's business evolution, capital allocation priorities, commercialization roadmap, and market positioning. The letter addresses historical capital raises, dilution, and a shift from technology development to commercialization, with anticipated commercial availability of the Fortis VPX platform in early 2027. While this is primarily forward-looking strategic guidance rather than a discrete operational event, the emphasis on commercialization transition, market positioning, and capital allocation strategy constitutes material operational disclosure that would inform investor assessment of the company's direction and execution capability.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 72%
filed 2026-07-21
The filing discloses a Limited Waiver and Consent Agreement under which the Company obtained Required Holders' consent to declare and pay a one-time cash dividend of $0.05 per share on Common Stock (payable August 3, 2026) and to enter into a stock repurchase plan for up to $20 million. While the filing also references a prior Securities Purchase Agreement for Series B Preferred Stock and Warrants, the material event disclosed in this 8-K is the dividend declaration and share repurchase authorization, which are capital allocation decisions affecting shareholders and would be material to a reasonable investor.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-21
The filing discloses a corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc., effective July 22, 2026, filed pursuant to Item 5.03 (Amendments to Articles of Incorporation or Bylaws). The accompanying ticker symbol change from WGRX to MEDS reflects a rebranding initiative. While primarily administrative, the name change is material to investors as it signals a strategic pivot toward AI-integrated healthcare solutions and represents a significant corporate identity shift that affects how the company is identified in the market.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-21
Item 2.01 discloses the completion of an acquisition on July 15, 2026, whereby Stark Novus Financial Inc.'s subsidiary Affinity Advisory Holdings Corp. acquired Affinity Advisory Network, LLC and AAN Wealth Advisors, LLC for aggregate consideration of $6.72 million in cash, 80,000 shares of Class A common stock, and 15% of the Buyer's equity, plus contingent earnout payments up to $1.312 million. This is a material acquisition event that would affect a reasonable investor's assessment of the registrant's financial position and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-21
The filing discloses the election of Michael Casey as a director and his appointment as chair of the Audit Committee, effective July 15, 2026. While the filing also mentions Michael McConnell's resignation as a director, the primary focus and substantive disclosure centers on Casey's appointment to the Board and his assumption of the Audit Committee chair role. The press release emphasizes Casey's qualifications and his return to the Board, making the appointment the salient event. Director and committee chair appointments are material governance changes affecting investor assessment of board composition and oversight.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-21
The filing discloses entry into an amended and restated unsecured promissory note for $50,000 principal with C/M Capital Master Fund, LP, maturing September 30, 2026, at 10% annual interest. This is a direct financial obligation creating new debt terms, disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). The amendment and restatement of existing debt, combined with the specific terms and maturity date, constitutes a material debt issuance event.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-21
The filing discloses two compensatory arrangements for officers and employees under Item 5.02: (1) a board determination regarding acceleration of approximately 1.6 million PSU awards in connection with the Merger Transactions closing on July 13, 2026, and (2) a grant of 360,000 restricted stock awards to officers and employees on July 15, 2026 under the 2023 Amended and Restated Omnibus Incentive Plan. Both are equity compensation arrangements materially affecting executive and employee incentive structures.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-21
The filing discloses resolution of a Nasdaq listing deficiency related to independent director and audit committee requirements. On January 26, 2026, ProCap received a deficiency letter for non-compliance with Nasdaq Listing Rules 5605(c)(2)(A) and 5605(b)(1). The Company cured this deficiency by appointing Benjamin Buchanan to the Board and audit committee (disclosed July 16, 2026), and on July 21, 2026, Nasdaq confirmed compliance and closed the matter. This is a governance event—specifically, remediation of a listing rule violation—that does not fit the specific categories of exec_appointment or exec_departure alone, as the core disclosure is the resolution of the compliance deficiency rather than the appointment itself.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-21
EX-99.1
This press release announces a strategic capital deployment initiative involving geographic expansion (Indonesia and Singapore), product portfolio broadening, and talent investment funded by cash reserves. While the disclosure describes operational and strategic business decisions rather than a discrete M&A transaction, covenant breach, or other specific event type, it represents a material strategic shift in the company's growth trajectory and capital allocation that would affect a reasonable investor's assessment of the registrant's direction and financial position.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 25%
filed 2026-07-21
EX-99.1
This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes "No final decision has been made" and "There is no guarantee that the uplisting will proceed." However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-21
EX-99.1
CLINUVEL announced that its American Depositary Shares (ADS) commenced trading on Nasdaq under ticker CUVL on 20 July 2026, completing an uplift from Level I to Level II ADR status. This is a material operational and capital-markets event affecting the registrant's listing status and accessibility to U.S. investors, but does not fit a discrete named event type (not M&A, not a delisting risk, not a debt or equity issuance per se). The uplift to Level II Nasdaq listing is a significant milestone for a foreign private issuer seeking broader U.S. market access.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
Upland Software appointed Jennifer Simon as Chief Financial Officer, effective August 17, 2026. Simon brings over 20 years of finance leadership experience in software and private equity, including prior roles at NextGen Healthcare and Quest Software, and will oversee financial planning, accounting, treasury, tax, and investor relations reporting to the CEO.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-21
Item 5.02
Lori Gustafson, Executive Vice President and Chief Brand and Digital Officer, is separating from Marriott Vacations Worldwide effective July 31, 2026, due to elimination of her position in an internal reorganization. While the disclosure includes severance details ($1,425,000 plus potential performance payment), the principal disclosed action is her departure from the company. The event is material as it involves a named executive officer's separation and would affect investor assessment of leadership continuity.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-21
Item 7.01
This Item 7.01 disclosure furnishes preliminary Assets Under Management (AUM) data for Voya's Investment Management segment as of June 30, 2026 ($377 billion total, broken down by asset type and client category). While the filing explicitly states the information is not "filed" under Section 18 and is furnished under Regulation FD, the AUM figures are material financial metrics that investors use to assess the scale and composition of the IM business prior to the full quarterly earnings release. This is a financial disclosure that does not fit the specific categories of earnings_release (which typically involves full results), debt_issuance, dividend_distribution, or other named financial events, making financial_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
The filing discloses Triumph Financial's financial results for the quarter ended June 30, 2026, including net income of $10.6 million ($0.44 per diluted share) and detailed operational metrics across segments (Payments, Factoring, Intelligence, Banking). The shareholder letter attached as Exhibit 99.1 provides comprehensive quarterly financial and operational performance analysis, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-21
Item 8.01
News Corporation discloses daily share repurchase activity under its authorized $1 billion repurchase program, with specific transaction details including 9.6 million Class A shares and 66,163 Class B shares purchased on the prior day for approximately $245.6 million in aggregate consideration. Share repurchases are a form of capital return to shareholders and constitute a material capital allocation decision affecting shareholder value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-21
EX-99.1
This press release announces completion of enrollment in a Phase 1 dose-escalation study of IPH4502, a proprietary Nectin-4 ADC, with preliminary data expected by year-end. The disclosure reports a clinical development milestone—enrollment completion in 76 patients—and preliminary safety and efficacy observations (favorable safety profile with limited hematological toxicity, objective responses in multiple tumor types). This is a material operational/clinical milestone for a clinical-stage biotech company that would affect investor assessment of the company's pipeline progress and the drug candidate's potential, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, impairment, or other named types). It is clearly operational/strategic in nature.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-21
Item 2.02
The filing discloses Synchrony Financial's second quarter 2026 earnings results via a press release dated July 21, 2026, reporting net earnings of $885 million ($2.59 per diluted share) and key financial metrics including purchase volume, loan receivables, and return on assets. This is a standard quarterly earnings disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. Item 2.02 discloses quarterly financial results including revenue of $1,105 million, operating income of $107 million, net income of $39 million, and adjusted EBITDA of $223 million, with detailed segment and geographic breakdowns. The news release is furnished as Exhibit 99.1 and a conference call is scheduled to discuss results, which are standard components of an earnings disclosure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-21
EX-99.1
This exhibit is a quarterly earnings release announcing Q2 2026 financial results for Telix Pharmaceuticals. The document discloses "Group revenue of US$247 million, up 7% quarter-over-quarter and up 21% year-over-year" and provides FY 2026 revenue guidance of "in excess of US$1 billion." The release includes detailed financial performance metrics, business unit results, and forward-looking guidance typical of a quarterly earnings announcement. Material to investors assessing the company's commercial performance and trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-21
Item 7.01
Forward Air disclosed entry into a non-binding MOU with one of its largest customers regarding a planned transition of services. The company expects to retain 50–75% of approximately $250 million in annual revenue from this customer and extend the contract term for at least two years. While this is a material customer relationship event affecting future revenue and operations, it does not fit the specific M&A taxonomy (ma_activity applies to acquisitions, dispositions, mergers, or changes of control, not customer contract renegotiations). The event is clearly operational and strategic in nature—a significant customer retention and contract extension—making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-21
EX-99.1
The exhibit announces the appointment of Christophe Van de Weyer as Head of Business Area Global Communications Platform and CEO of Vonage, and his addition to Ericsson's Executive Team. While the disclosure also includes Niklas Heuveldop's departure effective August 15, 2026, the principal disclosed action is the appointment of Van de Weyer to a critical executive role. This is material as it affects leadership of a significant business unit and the composition of the Executive Team.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-21
Item 8.01
Hines Global Income Trust, Inc. completed the acquisition of Design Center of the Carolinas, a 239,000 square-foot mixed-use retail and office property in Charlotte, for approximately $170.0 million on July 20, 2026. This represents a material capital deployment and significant portfolio expansion for the REIT.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
Forestar Group Inc. issued a press release on July 21, 2026 announcing its third quarter fiscal 2026 financial results for the period ended June 30, 2026. The disclosure includes consolidated financial statements (balance sheet and income statement), detailed operational metrics (lots sold, lot position), and forward guidance. Net income increased 9% to $35.9 million ($0.70 per diluted share), revenues increased 4% to $407.0 million, and pre-tax income increased 12% to $48.7 million. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-21
Item 8.01
PNC completed a public offering of $2 billion in aggregate principal amount of senior notes—$1 billion of 5.463% notes due 2037 and $1 billion of 4.831% notes due 2030. This is a material creation of direct financial obligations disclosed under Item 8.01, constituting a debt issuance that would affect a reasonable investor's assessment of the company's capital structure and leverage.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
Neptune Insurance Holdings Inc. disclosed its financial results for the second quarter ended June 30, 2026, via a press release and earnings presentation filed as Exhibits 99.1 and 99.2. The disclosure reports record revenue of $55.9 million (33% growth), record net income of $15.8 million (36% growth), and record adjusted EBITDA of $34.5 million (36% growth), along with per-share metrics and key performance indicators. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
Western Alliance Bancorporation issued a press release on July 21, 2026 reporting second quarter 2026 financial results, including net income of $268.8 million, diluted EPS of $2.36, and other key financial metrics. The Item 2.02 disclosure explicitly states the company "issued a press release reporting results for the fiscal quarter ended June 30, 2026" with exhibits attached (press release and earnings presentation), which is the standard form of earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-21
Item 3.02
Ares Sports, Media & Entertainment Opportunities LP completed an unregistered private placement of approximately $30.1 million in limited partnership units across multiple unit classes (Class S, Class I, Class A-S, and Class A-I) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-07-21
Item 2.05
The disclosure centers on a permanent closure of the Fayetteville, North Carolina manufacturing facility with approximately 1,750 job reductions and total pre-tax charges estimated between $535 million and $565 million. This is a classic workforce reduction and operational restructuring event under Item 2.05, with material financial impact including both cash exit costs and non-cash charges for accelerated depreciation and pension termination benefits, expected to improve operating income by $90 million in 2027 and $270 million annually thereafter.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-21
Item 8.01
The disclosure reports the final resolution of a material litigation between Miami International Holdings and Nasdaq that spanned nearly nine years (September 2017 to July 2026). The Order of Dismissal With Prejudice resolves all claims and counterclaims, and critically grants the Company unrestricted freedom to operate its exchanges, trading platforms, and technology without license or consent from Nasdaq or risk of infringement claims. This settlement removes significant operational and legal constraints that had been asserted by Nasdaq, making it material to investors' assessment of the Company's business prospects and competitive position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
KKR Real Estate Finance Trust Inc. issued an earnings release on July 21, 2026, announcing financial results for the quarter ended June 30, 2026. The disclosure reports a net loss of ($121.8) million, or ($1.95) per diluted share, and a Distributable Loss of ($36.4) million, or ($0.58) per diluted share, along with detailed portfolio, origination, and liquidity information. This is a standard quarterly earnings release filed under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-21
Item 3.02
The Fund sold 1,203,879 Class I common shares for $32.2 million during July 2026 in an unregistered offering exempt under Section 4(a)(2) and Regulation S, raising material capital through the sale of unregistered securities at NAV pricing.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-21
Item 8.01
The Fund declared and paid regular monthly distributions to shareholders across three share classes (Class I, S, and D) for July, August, and September 2026, with specific per-share amounts and payment dates.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-21
Item 1.01
Nutex Health entered into a First Amendment to its Payment Dispute Resolution Services Agreement with HaloMD, effective June 30, 2026, which materially restructures the fee payment model (from payment-on-award to pay-on-collected basis retroactive to May 2024), amends service fee structures, and extends the term through December 31, 2029. The company explicitly states it expects "a reduction in our overall arbitration related costs" as a result of this amendment and recent CMS fee reductions. While this is a material contract amendment affecting the company's cost structure and operational framework under the No Surprises Act, it does not fit the specific categories of M&A activity, debt issuance, or other named financial events—it is a material operational/contractual arrangement that would affect investor assessment of the registrant's cost profile and service delivery model.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 97%
filed 2026-07-21
Item 1.03
GoHealth, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 7, 2026, and emerged from bankruptcy on July 21, 2026, following confirmation of its prepackaged plan by the U.S. Bankruptcy Court for the District of Delaware on July 20, 2026. The plan converted the company into a limited liability company (New GoHealth, LLC), cancelled all existing equity interests, and issued 100% of new common interests to holders of Allowed First Lien Claims on a pro rata basis, fundamentally restructuring the company's capital structure and security holder rights.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-21
Item 1.01
GoHealth entered into a Senior Secured Credit Agreement establishing the Takeback Credit Facility totaling approximately $782.2 million ($20.0M new money + $173.9M senior takeback + $588.3M junior takeback), creating new direct financial obligations secured by substantially all assets as part of its emergence from Chapter 11 bankruptcy.
View raw filing on EDGAR →